<table id="i6460609f-91c9-4d4f-89bc-0d3b8a2c9fb3" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Clinical Results at Nine Months of Doxycycline Hyclate Capsules, 20 mg, as an Adjunct to SRP (Bioequivalent to Doxycycline Hyclate Tablets, 20 mg)</caption>
<col align="left" valign="top" width="40%"></col>
<col align="center" valign="bottom" width="20%"></col>
<col align="center" valign="bottom" width="20%"></col>
<col align="center" valign="bottom" width="20%"></col>
<thead>
<tr>
<th>Parameter</th>
<th colspan="3">Baseline Pocket Depth</th>
</tr>
<tr>
<th></th>
<th>0–3 mm</th>
<th>4–6 mm</th>
<th>≥ 7 mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>  (Doxycycline Hyclate Tablets<br/>  20 mg BID)</td>
<td>90</td>
<td>90</td>
<td>79</td>
</tr>
<tr>
<td>Number of Patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>  (Placebo)</td>
<td>93</td>
<td>93</td>
<td>78</td>
</tr>
<tr>
<td stylecode="TopRule">Mean Gain (SD<footnote id="t22">SD = Standard Deviation</footnote>) in ALv<footnote id="t27">ALv = Clinical Attachment Level</footnote>
</td>
<td stylecode="TopRule"></td>
<td stylecode="TopRule"></td>
<td stylecode="TopRule"></td>
</tr>
<tr>
<td>  Doxycycline Hyclate Tablets<br/>  20 mg BID</td>
<td>0.25 (0.29) mm</td>
<td>1.03 (0.47) mm<footnote id="t21">p&lt;0.050 vs. the placebo control group.</footnote>
</td>
<td>1.55 (1.16) mm<footnoteref idref="t21"></footnoteref>
</td>
</tr>
<tr>
<td>  Placebo</td>
<td>0.20 (0.29) mm</td>
<td>0.86 (0.48) mm</td>
<td>1.17 (1.15) mm</td>
</tr>
<tr>
<td stylecode="TopRule">Mean Decrease (SD<footnoteref idref="t22"></footnoteref>) in PD<footnote>PD = Pocket Dept</footnote>
</td>
<td stylecode="TopRule"></td>
<td stylecode="TopRule"></td>
<td stylecode="TopRule"></td>
</tr>
<tr>
<td>  Doxycycline Hyclate Tablets<br/>  20 mg BID</td>
<td>0.16 (0.19) mm<footnote id="t23">p&lt;0.010 vs. the placebo control group.</footnote>
</td>
<td>0.95 (0.47) mm<footnoteref idref="t23"></footnoteref>
</td>
<td>1.68 (1.07) mm<footnoteref idref="t23"></footnoteref>
</td>
</tr>
<tr>
<td>  Placebo</td>
<td>0.05 (0.19) mm</td>
<td>0.69 (0.48) mm</td>
<td>1.20 (1.06) mm</td>
</tr>
<tr>
<td stylecode="TopRule">% of Sites (SD<footnoteref idref="t22"></footnoteref>) with loss of<br/>ALv<footnoteref idref="t27"></footnoteref> ≥ 2 mm</td>
<td stylecode="TopRule"></td>
<td stylecode="TopRule"></td>
<td stylecode="TopRule"></td>
</tr>
<tr>
<td>  Doxycycline Hyclate Tablets<br/>  20 mg BID</td>
<td>1.9 (4.2)%</td>
<td>1.3 (4.5)%</td>
<td>0.3 (9.4)%</td>
</tr>
<tr>
<td>  Placebo</td>
<td>2.2 (4.1)%</td>
<td>2.4 (4.4)%</td>
<td>3.6 (9.4)%</td>
</tr>
<tr>
<td stylecode="TopRule">% of Sites (SD<footnoteref idref="t22"></footnoteref>) with BOP<footnote>BOP = Bleeding on Probing</footnote>
</td>
<td stylecode="TopRule"></td>
<td stylecode="TopRule"></td>
<td stylecode="TopRule"></td>
</tr>
<tr>
<td>  Doxycycline Hyclate Tablets<br/>  20 mg BID</td>
<td>39 (19)%<footnoteref idref="t23"></footnoteref>
</td>
<td>64 (18)%<footnoteref idref="t21"></footnoteref>
</td>
<td>75 (29)%</td>
</tr>
<tr>
<td>  Placebo</td>
<td>46 (19)%</td>
<td>70 (18)%</td>
<td>80 (29)%</td>
</tr>
</tbody>
</table>